Safety of SARS-CoV-2 BNT162b2 Vaccine in Elderly Patients from Japan - A Preliminary Assessment and A Call on Careful Pharmacovigilance


Autores/as

  • Erika Yamashita Medical Governance Research Institute, Tokyo, Japan
  • Akihiko Ozaki Medical Governance Research Institute, Tokyo, Japan
  • Masaharu Tsubokura Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
  • Morihito Takita Medical Governance Research Institute, Tokyo, Japan
  • Tetsuya Tanimoto Medical Governance Research Institute, Tokyo, Japan
  • Masahiro Kami Medical Governance Research Institute, Tokyo, Japan
  • Alfonso J. Rodriguez-Morales Grupo de Investigación Biomedicina, Faculty of Medicine, Fundacion Universitaria Autonoma de las Americas, Pereira, Colombia

Resumen

Vaccines are efficacious, effective and safe measures to control COVID-19. Despite phase 3 and 4 studies, some concerns should be addressed in certain populations regarding its specific vaccine safety. One of them is the safety of the elderly. The majority of enrollees in clinical studies on COVID-19 vaccines have been young to middle-aged individuals, with few exceptions.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2021-08-17

Número

Vol. 4 Núm. 1 (2021)

Sección

Cartas al Editor